| Objective To observe the clinical efficacy of “Shenluo Yu Chun Pills” in the treatment of polycystic ovary syndrome (PCOS) of the kidney yin deficiency with phlegm-stasis intermingling type. Methods A total of 52 PCOS patients with kidney yin deficiency and phlegm-stasis intermingling type were randomly divided into the treatment group (36 cases) and the control group (16 cases) at a ratio of 2:1. The treatment group was administered Shenluo Yu Chun Pills orally, while the control group received metformin orally, with a treatment course of 6 months. Changes in ovulation rate, clinical symptoms, signs, and blood indicators related to reproductive endocrine and glucose metabolism were monitored after treatment. Results The ovulation rates of the treatment group and the control group were 70.83% and 56.14% respectively, with the treatment group demonstrating superior efficacy (P＜0.05). The treatment group was more effective than the control group in improving menstrual cycle, menstrual flow, menstrual color, dry mouth, and other systemic symptoms (P＜0.01 or 0.05). BMI significantly decreased in both groups after treatment (P＜0.01 or 0.05), but no significant intergroup difference was observed (P＞0.05). Waist-to-hip ratio (WHR) of the treatment group decreased significantly (P＜0.05), whereas that of the control group showed no significant change (P＞0.05). Serum testosterone (T) and dehydroepiandrosterone sulfate (DHEA-S) in the treatment group decreased significantly (P＜0.01 or 0.05), though serum T in the control group also decreased significantly (P＜0.05), but there was no significant difference between the two groups (P>0.05). The insulin resistance index (HOMA-IR) of both groups showed significant decreases (P<0.01), with a more prominent reduction in the control group (P＜0.05). Conclusion Shenluo Yu Chun Pills can improve the clinical symptoms and signs of PCOS patients with kidney yin deficiency and phlegm-stasis intermingling group, reduce androgens and insulin resistance, thereby enhancing the ovulation rate. |